NCT03221075View on ClinicalTrials.gov

Clinical Implications of Azole-Resistant Aspergillosis in Hematological Malignancy

CompletedOBSERVATIONAL
Enrollment

203

Participants

Timeline

Start Date

March 1, 2017

Primary Completion Date

April 30, 2022

Study Completion Date

October 25, 2022

Conditions
Invasive Aspergillosis
Interventions
OTHER

Registry

There is no intervention.

Trial Locations (2)

6500

Radboud University Nijmegen Medical Center, Nijmegen

50931

University Hospital of Cologne, Cologne

All Listed Sponsors
collaborator

Radboud University Medical Center

OTHER

lead

University Hospital of Cologne

OTHER

NCT03221075 - Clinical Implications of Azole-Resistant Aspergillosis in Hematological Malignancy | Biotech Hunter | Biotech Hunter